echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Boston Immune has an exclusive option and license agreement with Baiji Shenzhou to develop new TNFR2 antibodies

    Boston Immune has an exclusive option and license agreement with Baiji Shenzhou to develop new TNFR2 antibodies

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Boston Immunotechnology and Therapeutics announced today that it has entered into an exclusive option and licensing agreement with Baiji Shenzhou to develop and commercialize Boston Immune's innovative tumor necrotizing group 2 (TNFR2) antibody.
    has obtained exclusive licenses to develop, produce and commercialize TNFR2 antibodies (BITR2101) in Asia (excluding Japan), Australia and New Zealand.
    the two companies plan to conduct Phase I clinical trials of BITR2101, including a combination with the anti-PD-1 antibody tislezumab in Baiji Shenzhou. Russell LaMontagne, chief executive of Boston Immune, said:
    The state is a global pharmaceutical company with a strong track record and an ideal partner to help develop the research TNFR2 antibody BITR2101.
    the collaboration with Baiji Shenzhou is a powerful validation of the Boston Immune antibody platform and an opportunity to demonstrate the potential of BITR2101 as a single drug and in collaboration with the immuno-checkpoint inhibitor tislezumab."
    TNFR2 is a member of the TNF-subject super family, which is highly expressed in many tumor types and has been shown to promote tumor cell growth.
    TNFR2 is also expressed on inhibitory immune cells in tumor micro-environments, including regulatory T-cells (Tregs) and inhibitory cells from myelin-like sources.
    TNFR2 has been identified as a potential driver of immune escape and tumor development, as well as immune checkpoint inhibitor resistance.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.